ArticleWorld journal of surgical oncology2025
CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThymic epithelial tumors (TETs) currently lack effective prognostic factors and novel treatment approaches, the aim of the study is to investigate the expression of CD55 in TETs and the relationship with clinicopathological characteristics and prognosis.
methodsFirstly, 250 TETs, including 206 thymoma and 44 thymic squamous cell carcinomas (TSCC), were retrospectively selected. Subsequently, the expression levels of CD55 protein and mRNA were assessed using immunohistochemistry (IHC) and qRT-PCR. Finally, the relationship among CD55, clinicopathological characteristics, and prognosis was analyzed.
resultsThe expression of CD55 mRNA and protein were higher in thymoma (p = 0.0148; p < 0.0001) and TSCC (both p < 0.0001) compared with normal thymus tissues. Immunohistochemically, the positive rate of CD55 was 80% (200/250) in TETs, mainly located in cytomembrane. 224 patients were successfully followed up, of which 33 patients developed progression. Univariate Cox regression analysis revealed that histological type, Masaoka-Koga stage, tumor completeness of resection, adjuvant therapy, CD55 mRNA, and protein (all p < 0.01) were significant factors affecting progression free survival (PFS). Multivariate Cox regression analysis showed that CD55 mRNA (p < 0.001), CD55 protein (p = 0.029), tumor completeness of resection (p = 0.010), and Masaoka-Koga stage (p = 0.006) were independent risk factors of PFS. In addition, Pearson's correlation analysis indicated a significant correlation between CD55 mRNA and protein, histological type, tumor completeness of resection, adjuvant therapy, and Masaoka-Koga stage (all p < 0.001). Unpaired T-test showed that the high expression of CD55 mRNA and protein were significantly associated with incomplete resection, higher histological grade, Masaoka-Koga stage, and adjuvant therapy (all p < 0.01). Furthermore, multivariate Cox analysis showed that CD55 mRNA (p < 0.001), CD55 protein (p = 0.037), tumor completeness of resection (p < 0.05) were independent risk factors of PFS in the high-risk TETs subgroup.
conclusionsThe high expression of CD55 was related to poor prognosis of TETs. Moreover, its significant association with worse outcomes in high-risk TETs subgroup further underscores it its potential as a prognostic marker and therapeutic target, especially in TSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.